Following a high-profile federal health briefing in late 2025, US prescriptions for leucovorin—an unproven autism drug—surged by more than 2,000% according to electronic health record data published in JAMA Network Open, highlighting how public announcements from officials like Robert F. Kennedy Jr. rapidly alter clinical prescribing patterns.
The dissemination of unverified medical interventions through official government channels creates immediate challenges for healthcare systems. When high-ranking officials promote off-label or unapproved treatments without waiting for robust clinical trial data, families navigating complex neurodevelopmental disorders face a landscape of heightened expectations mixed with unproven biological risks.
In Plain English: The Clinical Takeaway
- Leucovorin: A medication traditionally used to counteract the toxic side effects of chemotherapy drugs, not an FDA-approved treatment for autism spectrum disorder.
- Cerebral Folate Deficiency: A condition where the brain may not get enough folate (a type of vitamin B), which researchers are studying in some children with autism, though broad efficacy remains unproven.
- Off-Label Prescribing: The legal practice of prescribing an approved medication for a condition or age group not officially cleared by the Food and Drug Administration (FDA).
The September 2025 White House Briefing and Its Aftermath
On September 22, 2025, President Trump, Health and Human Services Secretary Robert F. Kennedy Jr., and FDA Commissioner Marty Makary held a White House briefing addressing autism and public health. During the session, Kennedy characterized leucovorin as “an exciting therapy that may benefit large numbers of children who suffer from autism.” Neither that claim nor concurrent warnings regarding acetaminophen use during pregnancy were supported by new clinical evidence or standard regulatory review.
The policy messaging immediately impacted clinical encounters nationwide. According to a study published in The Lancet in March 2026 by researchers JS Faust and ML Barnett from Harvard Medical School and Brown University, emergency departments administered acetaminophen to pregnant patients about 10% less often during the weeks following the briefing. Concurrently, prescription rates for leucovorin among pediatric patients experienced an upward trajectory.
Quantifying the Surge: Data from Epic Cosmos
To measure the tangible impact of the White House announcement, investigators analyzed the Epic Cosmos electronic health record database, which aggregates anonymized patient data across more than 1,800 hospitals and 41,500 clinics in the United States. A comprehensive study published on May 18, 2026, in JAMA Network Open by lead author Dr. Joshua Rothman, a clinical assistant professor of pediatrics at UC San Diego School of Medicine, tracked 838,801 children diagnosed with autism across 11.9 million outpatient encounters.
For roughly two years prior to the events, national baseline prescribing hovered at approximately 34 prescriptions per 100,000 outpatient encounters. Momentum initially shifted upward in February 2025 after a CBS Evening News segment highlighted a family reporting dramatic language improvements in their autistic child after starting the drug. Following the September White House briefing, however, prescription rates accelerated, climbing to more than 835 per 100,000 outpatient encounters by November 2025—representing a surge exceeding 2,000% above the baseline.
Dr. Joshua Rothman, lead author of the UC San Diego study, observed that households caring for autistic children constantly seek out interventions that might enhance social interaction and overall well-being, particularly when choices are scarce. "What this study shows is how quickly information shared through news coverage, social media, and public figures can influence real-world prescribing patterns, even before large clinical trials establish whether a treatment is truly safe and effective."
| Metric / Observation | Data Point / Percentage | Primary Source & Publication |
|---|---|---|
| Leucovorin Prescriptions (Pediatric Autism) | Surged over 2,000% above baseline by late 2025 | JAMA Network Open (May 2026) / Epic Cosmos |
| Acetaminophen Usage (Pregnant Patients) | Fell by approximately 10% in emergency departments | The Lancet (March 2026) / Harvard & Brown |
| Patient Population Analyzed (UCSD Study) | 838,801 children with autism (11.9 million encounters) | JAMA Network Open (May 2026) |
The FDA maintains rigorous review pathways to ensure that pharmacological treatments demonstrate verifiable efficacy and safety profiles before entering broad clinical use. Bypassing standard peer-reviewed scientific evaluation in favor of public executive briefings risks exposing pediatric populations to unnecessary pharmacological burdens and potential drug interactions without adequate clinical justification.
Contraindications & When to Consult a Doctor
Patients and caregivers must exercise caution when considering off-label medication use driven by media or political announcements.
References
- Rothman, J. et al. (2026). JAMA Network Open.
- Faust, J.S., & Barnett, M.L. (2026). Changes in paracetamol and leucovorin use after a White House briefing. The Lancet.
Disclaimer: This article is intended for informational and educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
